A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

The purpose of this study is to study SGN-B6A alone, with pembrolizumab, or with pembrolizumab and one of the chemotherapy drugs (cisplatin or carboplatin). The sponsor wants to find out what its side effects are and if it works for specific types of cancer. It is not yet know if SGN-B6A alone or with other drugs is better or worse than other treatments. This clinical trial uses an experimental drug. This means the Food and Drug Administration (FDA) hasn’t approved it for sale in the United States. This drug is called SGN-B6A. This clinical trial also uses pembrolizumab. The brand name for pembrolizumab is KEYTRUDA®. Pembrolizumab is approved by the FDA to treat several types of cancer. This clinical trial also uses the chemotherapy drugs cisplatin and carboplatin. Cisplatin and carboplatin are chemotherapy drugs approved by the FDA to treat multiple kinds of cancer. Cisplatin and carboplatin both use platinum to fight tumor cells. Thousands of patients with cancer have already been given cisplatin and carboplatin.

Are you Eligible? (Inclusion Criteria)

• Must be 18 years old or older. - Must not be known to be positive for human immunodeficiency virus (HIV). - Must not be breastfeeding, pregnant, or planning to become pregnant from time of informed consent until 2 months after final dose of study drug administration.